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 Present address.The group IIA human non-pancreatic secretory phospholipase A2 (hnp-sPLA2) is one of the enzymes
implied in the inﬂammatory process. In the course of our work on inhibitors of this enzyme we investi-
gated the inﬂuence of rigidity of the piperazine region on the biological activity. Several modiﬁcations
were explored. Various linkers, such as amide, urea, carbamate, or alkoxyphenyl were inserted between
the piperazine and the lipophilic chain. Also, modiﬁcation of the piperazine core to incorporate carbonyl
groups was studied. In an in vitro ﬂuorimetric assay using the human GIIA (HPLA2) and porcine pancre-
atic GIB enzymes, compound 60a (Y = phenoxy, R = C18H37, Z = CH2) had the optimal activity with an
IC50 = 30 nM on HPLA2. By means of molecular modelling we attempted to get informations towards com-
prehension of differences in activity.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Phospholipases A2 (PLA2) family members are esterases that
hydrolyze glycerophospholipids at the sn-2 position. The reaction
products are lysophospholipids and free fatty acids.1 Among them,
arachidonic acid (AA) is metabolized by enzymes such as cyclo-
oxygenases (Cox-1 and Cox-2) and lipo-oxygenases and lead to
the formation of prostaglandins, prostacyclin, thromboxans and
leukotrienes, with important roles in numerous physiological and
pathophysiological processes. Moreover, lyso Platelet-Activating
Factor (lyso-PAF) is acetylated by the PAF–acetyltransferase to
yield PAF, another well known pro-inﬂammatory mediator. The
superfamily of PLA2 comprises a number of very different proteins
that can be divided into ﬁve principal kinds of enzymes, the sPLA2s,
the cPLA2s, the Ca2+-independent PLA2s (iPLA2s), and the PAF acet-
ylhydrolases (PAF–AH), and the lysosomal PLA2s. Assignment of
the enzymes to a certain group is based on the catalytic mecha-
nism (His/Asp, Ser/Asp or Ser/ His/Asp hydrolase) as well as func-
tional and structural features.2ll rights reserved.
; fax: +33 (0)1 57 27 72 63.
ot.fr (A. Lamouri).The sPLA2s are small secreted proteins (14–18 kDa) usually con-
taining 5–8 disulﬁde bonds. This group of enzymes requires lM
levels of Ca2+ for catalysis. Generally sPLA2s show a high activity
with anionic phospholipid (PL) but only the GV and GX PLA2s also
hydrolyze phosphatidylcholine (PC) vesicles.3
The sPLA2s are found in plants,4 insects,5,6 molluscs,7 reptiles8
and mammals.9 sPLA2-IB is found in large amounts in the pancreas
and its principal function is the digestion of dietary lipids.10 This
enzyme was identiﬁed and cloned in other tissues such as lung,
spleen, kidney and ovary,11,12 and it has been proposed to be in-
volved in various physiological and pathophysiological responses
such as cell proliferation,13 cell contraction,14,15 lipid mediators re-
lease,16 acute lung injury17 and endotoxic shock.18
The sPLA2s appear to play a role in several inﬂammatory diseases.
GIIA PLA2 is present at high concentrations in synovial ﬂuid frompa-
tients suffering from rheumatoid arthritis.19 sPLA2s are involved in
adult respiratory stress syndrome (ARDS), inﬂammatory bowel dis-
ease, pancreatitis, sepsis20 and atherosclerosis.21–23 Mammalian
sPLA2s GIIA, GV, and GIID promote degranulation of mast cells,24
possess potent anticoagulant activity,25,26 bactericidal properties
and particularly the human GIIA, GV, GX and GXII and the murine










OZ = -CO- III
Z = -CH2- II
Figure 1.
N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600 3589The function of GIIA PLA2 in tumorigenesis is a controversial is-
sue. It is not clear if this enzyme serves as a tumour suppressor or
tumour promotor.29
In a previous paper, starting from our lead compound I30,31
(Fig. 1), we designed and synthesized piperazinic derivatives II
and III32 which were speciﬁc group II versus group I sPLA2 inhibi-
tors. 1-octadecyl-4-[40-(4,5-dihydro-(4H)-1,2,4-oxadiazol-5-one-
3-ylmethyl) benzyl] piperazine (II) and 1-octadecyl-4-[40-(4,
5-dihydro-(4H)-1,2,4-oxadiazol-5-one-3-yl methyl)benzoyl]piper-
azine (III) exhibited a micromolar range IC50 towards group IIA
PLA2, while inactive at 100 lM, the highest concentration used,
on group I PLA2 in an in vitro enzymatic assay. In addition, as com-
pound I was active in the carrageenan-induced oedema model
when ip administrated, but inactive per os because of its high lipo-
philicity (log P = 7), compound III was active either by ip or per os
routes, probably for its ability to get protonated at physiological
pH, leading to a better bioavailability.
In this last series, the activity appeared to be enhanced by rigid-
ifying the piperazinic ring either by introduction of the carbonyl or
branching directly the phenyl to the nitrogen as compared to a
methylene linker between piperazine and phenyle.32 Here we re-
port a SAR study by examining the inﬂuence of structural modiﬁ-
cations of II and III on inhibiting activity and selectivity towards
GIIA versus GIB sPLA2s. They included replacing either one nitro-
gen or both by different functions as amide, carbamate, urea and/
or branching directly an alkyloxyphenyl group, keeping a long
C10–C18 alkyl chain. We also diminished ﬂexibility of piperazine
ring by branching one (or two) methyl group(s) on one (or two)
carbon atom(s) of this cycle or replacing one (or two) methylene(s)
by one (or two) carbonyl(s) leading to substituted piperazinones
and piperazinediones. All of these derivatives were evaluated in
our enzymatic assay for their inhibitory potency towards GIB and
GIIA sPLA2s. This SAR was completed by a molecular modelling
study to explain the observed results.HN N N N

































Scheme 1. aReagents and conditions: (a) RCOCl, Et3N, dry toluene; (b) H2/Pd/C, EtOH, 50
THF/CH2Cl2; (g) R-X, NaH, DMF; (h) 12 N HCl, EtOH, reﬂux.2. Chemistry
To ovoid the N,N0-disubstitution, N-monosubstituted pipera-
zines were prepared as depicted in Scheme 1 either in two steps
starting from diphenylmethylpiperazine33 or by using an excess
of piperazine.32 Diphenylmethylpiperazine was treated with the
appropriate acid chloride to give the 4-acyl-1-diphenylmethylpip-
erazines 1b,d which were deprotected by hydrogenolysis into the
1-acylpiperazines 2b,d. The carbamates 4a,c were obtained after
preparing ﬁrst the carbonates 3a,c by esteriﬁcation of the corre-
sponding primary alcohol by phenyl chloroformate followed by
treatment with an excess of piperazine. In the same manner, intro-
duction of the urea function was obtained by addition of an excess
of piperazine to the chosen alkylisocyanate to give 5a,c. As for
alkylpiperazines 6a,c, 7a and 8a, they were prepared as described
by Boukli et al.32 starting from the corresponding 1-alkylbromide
and either piperazine or mono or dimethyl piperazines.
The introduction of an alkyloxyphenyl group was achieved as
outlined in Scheme 1 by O-alkylation of the commercially available
1-acetyl-4-(4-hydroxyphenyl)piperazine. This one was condensed
on the corresponding alkylbromide by means of its sodium salt ob-
tained with sodium hydride, leading to 9a,c,e. De-acetylation was
performed using hydrogen chloride and afforded N-alkyloxyphe-
nylpiperazines 10a,c,e as hydrochlorides.
The preparation of N-monosubstituted piperazinones (15a,c,
16a,c, 17b,d) and piperazinediones (18a,c, 21c) was performed fol-
lowing synthetic strategies depicted in Scheme 2. N-(2,2-Diethoxy-
ethyl)benzylamine was alkylated with the appropriate alkyl
bromide leading to N-alkyl-N-(2,2-diethoxyethyl)benzylamines
11a,c, followed by hydrogenolysis in the presence of catalytic palla-
dium. Using reported procedures34,35 with managed modiﬁcations,
condensation of these N-alkyl-2,2-diethoxyethylamines 12a,c with
benzyloxycarbonylaminoacetic acid, in the presence of DCC and
HOBt, allowed to obtain the corresponding carbamic acid benzyl es-
ters 13a,c which were cyclized into 1,4-disubstituted 3,4-dihydro-
2H-pyrazin-2-ones 14a,c in the presence of p-TsOH. Subsequent
catalytic hydrogenolysis in acidic conditions led to 1-alkylpipera-
zin-2-ones 15a,c as hydrochlorides.
Commercially available piperazin-2-one was treated with alkyl
bromide36 and acyl chloride to give 4-alkylpiperazin-2-ones 16a,c


















a: n-C18H37; b: n-C17H35; c: n-C14H29;
d: n-C13H27; e: n-C10H21



































































































Scheme 2. aReagents and conditions: (a) R-Br, K2CO3, Kl, CH3CN, reﬂux; (b) H2/Pd/C, EtOH, 40 C; (c) 12a,d, DCC, HOBT, Et3N, CH2Cl2, reﬂux; (d) p-TsOHH2O, toluene, 60 C;
(e) H2/Pd/C, EtOH, 12 N HCl; (f) R-Br, K2CO3, DMF; (g) RCOCl, Et3N, CH2Cl2; (h) RNH2, DMSO, 60 C; (i) RNH2, EtOH, reﬂux; (j) AcOH, 12 N HCl; (k) H2/Pd/C, AcOET.
3590 N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600N-Chloroacetyl glycine ethyl ester was treated with the
appropriate alkyl amine, then subsequent cyclization into 1-alkyl-
piperazine-2,5-diones 18a,c occured under heating in DMSO.37 N-
(2,2-Diethoxyethyl)oxamic acid ethyl ester was prepared from
oxalic acid diethyl ester and 2,2-diethoxyethylamine according to
a described procedure.38 Treatment with tetradecylamine under
reﬂux in ethanol then, cyclization of the so obtained N-(2,2-dieth-
oxyethyl)-N0-tetradecyl oxalamide 19c using concentrated hydro-
chloric acid,39 led to 1-tetradecyl-1,4-dihydropyrazine-2,3-dione
20c which was hydrogenated into 1-tetradecyl piperazine-2,3-
dione 21c in the presence of palladium.
The key intermediates to oxadiazolone formation are the nitrile
function. Depending on the case, this was either achieved through




































Scheme 3. aReagents and conditions: (a) p-ClCOPhCH2Cl, Et3N, CH2Cl2, 0 C; (b) NaCN, D
CH2Cl2, 0 C.vated reactants as outline in Scheme 3. Therefore chloride interme-
diates 22–27 were obtained by acylation of the monosubstituted
2b,d, 4a,c, 5a,c, 10a,c,e, disubstituted 7a and trisubstituted 8a
piperazines using 4-chloromethylbenzoyl chloride at low temper-
ature (0 C) to avoid reaction on the chloromethyl moiety as de-
scribed previously,23 nucleophilic substitution of the chloride
atom by sodium cyanide40 providing the nitriles 28–31, 33, 34
(Z = –CO–). Action of 4-bromomethylphenylacetonitrile which
was prepared according to the previously published procedure23
on 10a,c gave their corresponding cyanide 32a,c derivatives. At
last, activation of 4-aminophenylacetonitrile was performed using
2,2,2-trichloroethylchloroformate leading to the carbamate 35.
In the piperazinone and piperazine dione series, the syntheses


















MSO, 80 C; (c) p-BrCH2PhCH2CN, K2CO3, Kl, CH3CN, reﬂux; (d) CCl3CH2OCOCl, Et3N,
N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600 3591phenylacetonitrile 36c, 38a,c and benzonitrile 39a,c, 40b,d, 41a,c,
42c derivatives, are shown in Scheme 4.
Treatment of 1-tetradecylpiperazin-2-one hydrochloride 15c
with (4-bromomethyl) phenylacetonitrile in the presence of potas-
sium iodide conducted to 4-(4-cyanomethylbenzyl)-1-tetradecyl-N NHR
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Scheme 4. aReagents and conditions: (a) p-NCCH2–Ph–CH2Br, K2CO3, Kl, CH3CN,
reﬂux; (b) p-ClCH2–Ph–COCl, Et3N, benzene; (c) NaCN, DMSO, 50 C; (d) (i) NaH,





























Scheme 5. aReagents and conditions: (a) NH2OH 50% aq, EtOH, reﬂux; (b) ClCOOPh, Et3piperazin-2-one 36c in alkaline conditions and under reﬂux in
acetonitrile.41
Using 4-chloromethylbenzoyl chloride, the 1-alkylpiperazin-2-
one hydrochlorides 15a,c were acylated. The chloro atom of the
1-alkyl-4-(4-chloromethylbenzoyl)piperazin-2-one intermediates
37a,c was substituted by sodium cyanide in DMSO,42 leading to
1-alkyl-4-(4-cyanomethylbenzoyl)piperazin-2-ones 38a,c.
In a same manner, 1-alkylpiperazin-3-ones 16a,c, 1-acylpipera-
zin-3-one 17b,d, 1-alkylpiperazine-2,5-dione 18a,c and 1-tetrade-
cylpiperazine-2,3-dione 21c were deprotonated by sodium
hydride and alkylated36 with (4-bromomethyl)benzonitrile to give
1-alkyl-4-(4-cyanobenzyl)piperazin-3-ones 39a,c, 1-acyl-4-(4-cya-
nobenzyl)- piperazin-3-ones 40b,d, 1-alkyl-4-(4-cyanobenzyl)
piperazine-2,5-diones 41a,c and 4-(4-cyanobenzyl)-1-tetradecyl-
piperazine-2,3-dione 42c, respectively.
All cyano derivatives 28–36 and 38–42 were transformed into
the amidoximes 43–56 by aqueous hydroxylamine.43 The oxadiazo-
lone derivatives 57–70 were then obtained after treatment with
phenyl chloroformate according to Kohara et al.44 adapted to our
use, followed by cyclization in reﬂuxing toluene of the crude
carbonate intermediates (Scheme 5). Compounds 71 and 72
(Z = –CO–NH–) were obtained by reacting 64with the mono substi-
tuted piperazines 5a,c and 6a,c, respectively.
3. Results and discussion
All the synthesized compounds were evaluated as sPLA2 inhib-
itors in in vitro enzymatic tests using either human PLA2 GIIA
(HPLA2) or porcine pancreatic PLA2 GIB (PPLA2) (see biological sec-
tion) and the results are reported in Tables 1 and 2. The log P values
were calculated using the Rekker’s hydrophobic fragmental con-
stants method.49
Our previous work32 showed that introduction of a piperazine
ring (compound II) in the structure of compound I did not affect
neither the inhibitory effect against GIIA sPLA2 with IC50 of 2.2
and 3.4 lM, respectively, nor the selectivity GIIA/GIB (Table 1). In
addition, it offered the ability of protonation at physiological pH
then lowering the lipophilicity supposed to enhance biodistribu-
tion. It appeared also that rigidifying the piperazine ring by replac-
ing Z = CH2, compound II, by Z = CO, compound III, with IC50 of 2.2
and 0.8 lM, respectively, permitted to reach the value of Lilly ref-
erence, LY31172745 (IC50 = 0.47 lM), measured in the same condi-
tions as ours.
Starting with these results we undertook in one hand to rigidify
more the piperazine ring from the outside by replacing its two















N, CH2Cl2, 0 C; (c) toluene, reﬂux; (d) 5a,c, toluene, reﬂux; (e) 6a,c, toluene, reﬂux.
Table 1
Inhibition of the enzymatic activity of human PLA2 (GIIA) HPLA2 and porcine
pancreatic PLA2 (GIB) PPLA2 by piperazine derivatives of compound I, using the
ﬂuorimetric assay




Compd R Y Z Log Pa IC50b (lM)
HPLA2 PPLA2
57b n-C17H35 –CO– –CO– 7.0 1.6 >75
57d n-C13H27 –CO– –CO– 4.9 2.7 >75
58a n-C18H37 –O–CO– –CO– 6.9 0.15 59.77
58c n-C14H29 –O–CO– –CO– 4.9 2.7 33
59a n-C18H37 –NH–CO– –CO– 6.9 0.33 24.54
59c n-C14H29 –NH–CO– –CO– 4.8 4.88 42.23
60a n-C18H37 –O–C6H4– –CH2– 10 0.03 7.41
60c n-C14H29 –O–C6H4– –CH2– 7.9 >10 >10
61a n-C18H37 –O–C6H4– –CO– 10.2 0.07 7.4
61c n-C14H29 –O–C6H4– –CO– 8.1 0.22 5.33
61e n-C10H21 –O–C6H4– –CO– 6.1 3.25 21.57
71a n-C18H37 Deleted –CO–NH– 7.3 0.05 >50
71c n-C14H29 Deleted –CO–NH– 5.2 2.04 >25
72a n-C18H37 –NH–CO– –CO–NH– 6.3 0.29 3.58
72c n-C14H29 –NH–CO– –CO–NH– 4.3 3.04 33
I31 7.08 3.4 >100
II32 n-C18H37 Deleted –CH2– 7.67 2.2 >100
III32 n-C18H37 Deleted –CO– 7.85 0.8 >100
LY31172745 0.47 8
a Calculated using Rekker’s hydrophobic fragmental constants.49
b Determined with three or more independent sample preparations using the
ﬂuorimetric binding assay and given as mean value with SD less than 20% of the
mean value.
3592 N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600branching a phenyl group directly on one of the nitrogens (Table
1). In another hand, the piperazine ring was also rendered less ﬂex-
ible from the inside by substitution with one or two methyl groups
or introducing carbonyl groups in the place of one or two methyl-
enes (Table 2).Table 2







Compd R A B C
62a n-C18H37 CH2 CH2 CHCH3
63a n-C18H37 CHCH3 CH2 CHCH3
65c n-C14H29 CO CH2 CH2
66a n-C18H37 CO CH2 CH2
66c n-C14H29 CO CH2 CH2
67a n-C18H37 CH2 CO CH2
67c n-C14H29 CH2 CO CH2
68b n-C17H35CO CH2 CO CH2
68d n-C13H27CO CH2 CO CH2
69a n-C18H37 CH2 CO CH2
69c n-C14H29 CH2 CO CH2
70c n-C14H29 CO CO CH2
III32 n-C18H37 CH2 CH2 CH2
IV32 n-C18H37 CH2 CH2 CH2
LY31172745
a Calculated using Rekker’s hydrophobic fragmental constants.49
b Determined with three or more independent sample preparations using the ﬂuorime
* Not determined.At the ﬁrst glance, results reported in Tables 1 and 2 show that
all the synthesized compounds are active on HPLA2 with a very
high selectivity for this group II enzyme versus GIB. Comparing
the global lipophilicity of the molecules calculated using Rekker’s
hydrophobic fragmental constants,49 it appears that the best re-
sults are obtained with log PP 7 as found for our initial leader
compound I with the advantage that, in some of them, the amine
function of the piperazine allows protonation, then lowering the
calculated lipophilicity of the free base (compounds 60, 61, 62,
63, 65, 67, 68 and 71) by about three log P units.
3.1. Rigidiﬁcation outside the piperazine ring
Table 1 shows that replacing the ﬁrst methylene group of the al-
kyl chain of III by a carbonyl as in 57b divides the activity by two as
shown by the IC50 of 0.8 and 1.6 lM, respectively. A better result
was obtained with Y = OCO to reach a 10 times more active com-
pound (58a, IC50 = 0.15 lM) and 5 times with Y = NHCO in 59a
(IC50 = 0.33 lM). It is relevant noting here that 57b, 58a and 59a
being isolipophilic, the difference cannot involve lipophilic interac-
tions but appears as a consequence of the modiﬁed functional
groups introduced. One could hypothesize that an unfavourable ef-
fect of the C@O in the amide 57b could be compensated by the
oxygen in the carbamate 58a or the NH in the urea 59a as the abil-
ity of a hydrogen bonding in the catalytic site.
A very good result is also obtained by intercaling a phenoxy
moiety between the nitrogen and the alkyl chain as shown by com-
paring 60a and II (0.03 and 2.2 lM, respectively) in one hand, 61a
and III (0.07 and 0.8 lM, respectively) leading to at least a ten
times gain in activity.
The same advantage is reached by replacing one of the amine
functions of II by an ureide in compound 71a (IC50 = 0.05 lM) or
both, as in 72a (IC50 = 0.29 lM).
3.2. Variation inside the piperazine
Table 2 shows that substituting one of the methylenes of the







D Z n Log Pa IC50b (lM)
HPLA2 PPLA2
CH2 CO 1 8.4 0,58 >100
CH2 CO 1 8.9 0.23 >100
CH2 CH2 1 4.7 30 >85
CH2 CO 1 5.8 1.7 >100
CH2 CO 1 3.8 10 >100
CH2 CH2 0 6.5 0.97 >50
CH2 CH2 0 4.5 >25 >25
CH2 CH2 0 5.3 26 >50
CH2 CH2 0 3.3 >75 >75
CO CH2 0 5.7 1.3 >100
CO CH2 0 3.6 57 >100
CH2 CH2 0 nd* 40.7 >75
CH2 CO 1 7.85 0.8 >100
CH2 CH2 0 7.37 5.08 >100
0.47 8
tric binding assay and given as mean value with SD less than 20% of the mean value.
N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600 3593(compound 63a) has few effect on the activity, compounds 62a,
63a and III bearing IC50 of the same range, 0.58, 0.23 and 0.8 lM,
respectively. In the other hand, replacing a methylene of the piper-
azine by a carbonyl beside the alkyl chain decreases the activity,
compound 66a (IC50 = 1.7 lM) being half time less active as III
and this result could be compared to the lost of activity between
III and 57b. Introduction of a carbonyl in the piperazinic ring
was attempted to obtain more or less ﬂexible compounds but it
was dependent on the success of the synthesis for this series. For
example, we could not assess through our synthesis, compounds
bearing carbonyls in the piperazine as in 67–70, with Z = CO and
n different from zero. Lacking with these two spacers is, with our
experience,30,31 very unfavourable to activity as shown by compar-
ing the IC50 of III (Z = CO, n = 1, IC50 = 0.8 lM), II (Z = CH2, n = 1,
IC50 = 2.2 lM) and IV (Z = CH2, n = 0, IC50 = 5.08 lM) in one hand,
and those of 66c (10 lM) and 65c (30 lM) in the other hand. Nev-
ertheless when the CO group is close to the oxadiazolone bearing
moiety, compounds more or less active as III were obtained as
shown by the IC50 of 67a (0.97 lM) and 69a (1.3 lM), then from
four to ﬁve times more active than IV, in spite of their lower
lipophilicity.
As it appeared that lipophilicity was not concerned in this ser-
ies, we wondered if other interactions could be involved to explain
these results either intramolecular or in relation with the active
site. That is the reason why some of themwere selected to be stud-
ied through molecular modelling.
First, the geometries of the molecules were optimized for all
the degrees of freedom at the ab initio RHF level using the dou-
ble f basis set 6-31G.46 For several compounds, an additional
conformational analysis was performed as for 61 and
reoptimization of the local minima thus trapped. All the calcula-
tions were performed using the GAUSSIAN software.47 For all the
studied molecules, the alkyl appendage was limited to a propyl
substituent.
Optimization of the geometries shows that most of the com-
pounds (compounds III, 57, 58, 59, 61, 63 and 66) with Z = CO
and n = 1 have nearly the same proﬁle as illustrated in Figure 2
(completed in Supplementary data) with the same ‘up’ orientation
of the oxadiazolone ring with regard to the rest of the molecule. In
57, 58 and 59, the carbonyl on each site of the piperazine nitrogensFigureﬁxes the rigid geometry due to the amide function. This feature
also appears with one carbonyl in III, 61, 63 and 66. The conforma-
tional analysis of the 61 molecule allows locating four conformers
with a very similar relative energy (see Supplementary data). In re-
turn, when Z = CH2, n = 0 (compounds IV, 67, 68, 69 and 70), the
oxadiazolone moiety adopts a very different ‘down’ position which
could explain the less activity of these molecules (Fig. 3). The ureas
71 and 72, as for them, appear in a third type privileged conforma-
tion as a consequence of the lengthening between the piperazine
and the phenyl rings, which seems favourable, as shown by their
activity (Fig. 4).
The electrostatic potential was computed at the same level as
the geometry optimization. The 3D envelope is drawn at
20 kcal/mol level. All the maps show a strong electrostatic poten-
tial at the level of the oxadiazolone and several others depending
of the functional groups introduced to rigidify the piperazine ring.
The characteristic potential appears in the amide region for Z = CO
in 57, 61, 63 and III (Fig. 5). In compounds bearing another car-
bonyl in the Y region, outside (57, 58, 59) or inside (66) another
important electrostatic potential appears when compared to III
which could moderate the activity depending on other factors as
hydrogen bonding abilities evoked previously (Fig. 6). It is to note
that a similar electrostatic proﬁle is shown in 69 with the two car-
bonyls inside the piperazine ring leading to comparable IC50. In an-
other hand, those two negative wells joint together in 70 (Fig. 7)
could explain the poor activity of this last.
For 60 and the compounds where Z = CH2 (IV, 65), the nitrogen
character becomes sp3 and their lone pairs generate their own iso-
contour depending on the geometry.
4. Conclusions
We have shown that in the oxadiazolone series of PLA2 GIIA
inhibitors, rigidifying the molecules by means of a piperazine ring
whose ﬂexibility and conformation can be modulated through dif-
ferent functional groups could enhance the activity. The best com-
pounds here were those bearing a phenoxy group directly attached
to the nitrogen of the piperazine. The advantage is to keep the pro-
tonation ability of the nitrogen, useful for bioavailability. The intro-
duction of carbonyls not only suppressed this protonation, but also2.
Figure 4.
Figure 3.




All materials were obtained from commercial suppliers and
used without further puriﬁcation. Thin layer chromatography
was performed on TLC plastic sheets of Silica Gel 60F254 (layer
thickness 0.2 mm) from Merck. Column chromatography puriﬁca-
tion was carried out on silica gel 60 (70–230 mesh ASTM, Merck).
All melting points were determined on a digital melting point
apparatus (electrothermal) and are uncorrected. The structure of
all compounds was conﬁrmed by IR and NMR spectra. IR spectra
were obtained in parafﬁn oil with an ATI Mattson Genesis SeriesFTIR spectrometer; 1H and 13C NMR spectra were recorded at
200 MHz and 50 MHz, respectively, in CDCl3 or otherwise speci-
ﬁed, on a BRUKER AC 200 spectrometer using hexamethyldisilox-
ane (HMDS) as an internal standard. Chemical shifts are given in
ppm and peak multiplicities are described as follows: s, singlet,
ls, large singlet, d, doublet, t, triplet, m, multiplet. Elemental anal-
yses were obtained from the ‘Service Régional de Microanalyse’
(Université Pierre et Marie Curie, Paris, France) and were within
± 0.4% of theoretical values.
5.2. In vitro biological activity assay
PLA2 activity was evaluated by the method of Radvanyi et al.48
Enzymes used were two secretory enzymes: human recombinant
PLA2 of group II, HPLA2 (GIIA) and porcine pancreatic PLA2 of group
I, PPLA2 (GIB). Palmitoyl-2-(10-pyrenyldecanoyl)-sn-glycero-3-
Figure 5.
Figure 6.
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the ﬂuorometric assay which was performed with a Perkin–Elmer
LS50 luminescence spectrometer in a unit dosage polystyrene cell
having a size of 1 cm. The concentration of the ﬂuorescent sub-
strate was determined by UV Unicam spectrometry in a quartz cell.
The experimental protocol was the same as described in our previ-
ous publications.30–325.3. 4-Diphenylmethyl-1-octadecanoylpiperazine (1b)
A solution of N-diphenylmethyl piperazine (20 g, 79 mmol) in
Et3N (12 mL, 120 mmol) and dry toluene (200 mL) was cooled in
an ice bath. Octadecanoyl chloride (26.4 g, 100 mmol) solubilized
in dry toluene (150 mL) was added dropwise and the mixture
was stirred at 0 C for 1 h. The organic layer was washed with a
Figure 7.
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(MgSO4), ﬁltration and evaporation, the residue was chromato-
graphed on a silica gel column using CH2Cl2 as eluent to yield
36.85 g (90%) of 1b as a yellow oil. Rf 0.4 (CH2Cl2/MeOH, 95:5,
v/v); IR cm1: 1647 (C@O), 1600 (C@Car); 1H NMR: d 6.98–7.25
(m, 10H), 4.05 (s, 1H), 3.44 (t, 2H, J = 4.7 Hz), 3.27 (t, 2H,
J = 4.9 Hz), 2.19 (t, 4H, J = 4.9 Hz), 2.09 (t, 2H, J = 8 Hz), 1.38 (t,
2H, J = 6.8 Hz), 1.08 (ls, 28H), 0.71 (t, 3H, J = 6.4 Hz).
5.4. 1-Octadecanoylpiperazine (2b)
To a solution of the amide 1b (24 g, 69 mmol) in EtOH (150 mL)
was added 100 mg Pd–C, and this mixture was warmed (50 C)
with stirring under hydrogen atmosphere. After disappearance of
the starting material (12 h) as shown by TLC, the suspension was
ﬁltered and the catalyst washed several times with EtOH. The sol-
vents were evaporated and the residue chromatographed on a sil-
ica gel column using CH2Cl2 as eluent to yield 10 g (72.5%) of 2b as
a yellow powder: mp 98 C; Rf 0.25 (CH2Cl2/MeOH, 90:10, v/v); IR
cm1: 3380 (N–H), 1647 (C@O); 1H NMR (CD3OD): d 3.65 (t, 4H,
J = 4.7 Hz), 3.24 (ls, 1H), 3.01 (ls, 4H), 2.34 (t, 2H, J = 7.6 Hz), 1.52
(t, 2H, J = 6.7 Hz), 1.22 (ls, 28H), 0.85 (t, 3H, J = 5.8 Hz).
5.5. Octadecylphenylcarbonate (3a)
A solution of 1-octadecanol (10 g, 37 mmol) in Et3N (6.25 mL,
44 mmol) and freshly distilled THF (80 mL) was cooled in an ice
bath. A solution of phenyl chloroformate (5.63 mL, 44 mmol) in
THF (30 mL) was added dropwise and the mixture was stirred at
0 C for 1 h. The solvent was evaporated and the residue, taken
up in CH2Cl2, was washed with a saturated Na2CO3 solution and
twice with water. After drying (MgSO4), ﬁltration and evaporation,
the residue was chromatographed on a silica gel column using
CH2Cl2 as eluent to yield 9.42 g (66%) of carbonate 3a as an oil:
Rf 0.52 (CH2Cl2/MeOH, 98:2, v/v); IR cm1: 1753 (C@O), 1110
(C–O); 1H NMR: d 7.35–7.08 (m, 5H), 4.17 (t, 2H, J = 6.6 Hz),
1.69–1.64 (m, 2H), 1.19 (ls, 30H), 0.81 (t, 3H, J = 6.6 Hz).
5.6. N-Octadecyloxycarbonylpiperazine (4a)
A mixture of carbonate 3a (9.42 g, 24 mmol) and piperazine
(20.77 g, 241 mmol) in 100 mL THF/CH2Cl2 (3:1) was stirred atroom temperature for 1 h. The solvents were evaporated; the res-
idue was taken up in CH2Cl2 and washed twice with water. The or-
ganic phase was then dried over MgSO4, ﬁltered and concentrated
in vacuo. The product was crystallized in acetone to yield 4.5 g
(76%) of 4a as white crystals: mp 54 C; Rf 0.30 (CH2Cl2/MeOH,
90:10, v/v); IR cm1: 3425 (NH), 1709 (CO), 1198 (C–O); 1H
NMR: d 4.00 (t, 2H, J = 6.6 Hz), 3.37 (t, 4H, J = 5.2 Hz), 2.75 (t, 4H,
J = 4.9 Hz), 1.93 (s, 1H), 1.55 (t, 2H, J = 6.8 Hz), 1.19 (ls, 30H), 0.81
(t, 3H, J = 6.7 Hz).
5.7. N-Octadecylaminocarbonylpiperazine (5a)
A mixture of octadecyl isocyanate (4.42 g, 15 mmol) and piper-
azine (13 g, 151 mmol) in CH2Cl2 (70 mL) was stirred at room tem-
perature for 1 h. The solution was washed twice with water. The
organic phase was then dried over MgSO4, ﬁltered and concen-
trated to yield 5.21 g (91%) of 5a as white crystals: mp 72 C; Rf
0.46 (CH2Cl2/MeOH/NH4OH, 80:20:2, v/v/v); IR cm1: 3364 (NH),
1620 (C@O); 1H NMR: d 4.68 (t, 1H, J = 5 Hz), 3.26 (t, 4H,
J = 5.2 Hz), 3.14 (q, 2H, J = 7 Hz), 2.77 (t, 4H, J = 4.8 Hz), 1.73 (s,
1H), 1.42 (t, 2H, J = 6.4 Hz), 1.19 (ls, 30H), 0.81 (t, 3H, J = 6.2 Hz).
5.8. 3-Methyl-1-octadecylpiperazine (7a)
A mixture of 45 g (0.45 mol) of commercially available 2-meth-
ylpiperazine and 15 g (45 mmol) of octadecylbromide in 250 mL of
THF/CH2Cl2 (50:50, v/v) was stirred at room temperature for 3 h.
After evaporation of the solvents, the residue was taken up in
CH2Cl2 and washed twice with water. The organic layer was then
dried over MgSO4, ﬁltered and concentrated to afford 12.7 g
(80%) of 7a as a white solid: mp 48.5 C. Rf 0.12 (CH2Cl2/MeOH,
80:20, v/v); IR cm1: 3440 (N–H); 1H NMR: d 3.00–2.2 (m, 9H),
1.50–1.3 (m, 2H), 1.20 (1s, 30H), 0.98 (d, 3H, J = 6 Hz), 0.81 (t, 3H,
J = 6.6 Hz).5.9. 1-Acetyl-4-(4-octadecyloxyphenyl)piperazine (9a)
To a solution of 1-acetyl-4-(4-hydroxyphenyl)piperazine
(2.36 g, 0.059 mol) in DMF (100 mL) was added dropwise a suspen-
sion of NaH (60% dispersion in mineral oil, 10.8 g, 0.049 mol) in
DMF (30 mL). The mixture was stirred at room temperature for
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was added dropwise. The resulting mixture was warmed (60 C)
with stirring for 2 h. After cooling, water (100 mL) was added
and the precipitated crystals were collected, washed with water
and dried to provide 9a (15.57 g, 95%) which was used in the next
step without puriﬁcation: mp 117 C; Rf 0.40 (CH2Cl2/MeOH, 95:5,
v/v); IR cm1: 1621 (C@O), 1597 (C@Car); 1H NMR: d 6.85 (q, 4H,
J = 9.1 Hz), 3.89 (t, 2H, J = 6.5 Hz), 3.73 (t, 2H, J = 4.6 Hz), 3.60 (t,
2H, J = 4.7 Hz), 3.01 (d, 4H, J = 4.3 Hz), 2.12 (s, 3H), 1.80–1.7 (m,
2H), 1.19 (ls, 30H), 0.81 (t, 3H, J = 6.1 Hz).
5.10. 1-(4-Octadecyloxyphenyl)piperazine dihydrochloride
(10a)
A mixture of 9a (15 g, 33 mmol) in EtOH (150 mL) and 12 N HCl
(30 mL) was warmed to reﬂux for 3 h. The solvent was evaporated
under reduced pressure to give a viscous solid. The taking up in
MeOH (100 mL) made precipitate crystals which were collected
and dried to provide 14 g (85%) of 10a: mp 220 C; Rf 0.15
(CH2Cl2/MeOH, 90:10, v/v); IR cm1: 1595 (C@Car), 1146 (C–O);
1H NMR: d 9.96 (ls, 1H), 7.69 (d, 2H, J = 8.7 Hz), 6.87 (d, 2H,
J = 8.7 Hz), 3.98 (ls, 8H), 3.83 (t, 2H, J = 6.5 Hz), 1.68–1.6 (m, 2H),
1.14 (ls, 30H), 0.81 (t, 3H, J = 6.1 Hz).
5.11. N-(2,2-Diethoxyethyl)-N-tetradecylbenzylamine (11c)
To a mixture of N-(2,2-diethoxyethyl)benzylamine (51.6 g,
0.23 mol), potassium carbonate (63.9 g, 0.46 mol) and potassium
iodide (1 g, 6.02 mmol) in acetonitrile (700 mL) was added 1-bro-
motetradecane (64 g, 0.23 mol) and the reaction mixture was re-
ﬂuxed for 12 h. After cooling to room temperature, the mixture
was ﬁltered and evaporated under reduced pressure. The crude
residue was taken up into CH2Cl2 and washed with water. The or-
ganic layer was dried over MgSO4, then ﬁltered and evaporated un-
der reduced pressure. The resulting residue was puriﬁed by silica
gel column chromatography using CH2Cl2/MeOH (99.5:0.5, v/v)
as eluent to obtain 11c as a colorless oil (88.5 g, 91%): Rf 0.46
(CH2Cl2/MeOH, 97:3, v/v); IR cm1: 1603 (C@Car), 1118, 1065
(CH2O); 1H NMR: d 7.30–7.13 (m, 5H), 4.47 (t, 1H, J = 5.16 Hz),
3.56 (s, 2H), 3.62–3.35 (m, 4H), 2.55 (d, 2H, J = 5.17 Hz), 2.41 (t,
2H, J = 7.23 Hz), 1.39 (t, 2H, J = 6.87 Hz), 1.19–1.07 (m, 28H), 0.81
(t, 3H, J = 6.37 Hz).
5.12. N-(2,2-Diethoxyethyl)tetradecylamine (12c)
To a solution of 11c (88 g, 0.2 mol) in ethanol (300 mL) was
added 10% Pd–C (0.5 g). The suspension was shaken vigorously un-
der H2 (50 PSI) and heated at 40 C for 48 h. After cooling to room
temperature and ﬁltration through a glass frit funnel covered with
a layer of Celite 545, the solvent was removed under reduced pres-
sure and the resulting residue was puriﬁed by column chromatog-
raphy on silica gel using CH2Cl2 to afford 12c as a colorless oil (59 g,
90%): Rf 0.3 (CH2Cl2/MeOH, 95:5, v/v); IR cm1: 3391 (NH), 1125,
1069 (CH2O); 1H NMR: d 4.59 (t, 1H, J = 5.55 Hz), 3.57 (m, 4H),
2.63 (d, 2H, J = 5.57 Hz), 2.58 (t, 2H, J = 7.25 Hz), 2.32 (s, 1H), 1.45
(m, 2H), 1.15 (m, 28H), 0.81 (t, 3H, J = 6.40 Hz).
5.13. N-Tetradecyl carbamic acid benzyl ester (13c)
A mixture of 12c (53.8 g, 0.16 mol), N-carbobenzyloxyglycine
(33.1 g, 0.16 mol), triethylamine (46 mL, 0.3 mol) and 1-hydroxy-
benzotriazole (26 g, 0.19 mol) were dissolved in dichloromethane
(120 mL). The solution was stirred for 10 min then N,N0-dicyclo-
hexylcarbodiimide (37 g, 0.18 mol) was added and the reaction
mixture was heated to reﬂux for 2 h. After cooling to room temper-
ature, the mixture was ﬁltered. The organic layer was washed withwater and brine, subsequently, then dried over MgSO4, and con-
centrated in vacuo. The crude residue was puriﬁed by silica gel col-
umn chromatography using CH2Cl2/MeOH (99:1, v/v) as eluent to
obtain 13c as a colorless oil (82 g, 96.5%): Rf 0.43 (CH2Cl2/MeOH,
98:2, v/v); IR cm1: 1720 (OC@O), 1649 (NC@O); 1H NMR: d 7.17
(m, 5H), 5.85 (ls, 1H), 5.01 (s, 2H), 4.54 (t, 1H, J = 5.26 Hz), 4.02–
3.92 (m, 2H), 3.65–3.48 (m, 2H), 3.20 (m, 6H), 1.44 (m, 2H), 1.17
(m, 22H), 1.09 (t, 6H, J = 6.98 Hz), 0.79 (t, 3H, J = 6.20 Hz).
5.14. 3,4-Dihydro-1-tetradecyl-2H-pyrazin-2-one (14c)
To a solution of compound 13c (23 g, 47 mmol) in toluene
(250 mL) was added a catalytic amount of p-TsOH (936 mg,
4.7 mmol). After heating to 60 C for 3 h, the solution was allowed
to cool to room temperature and washed with water. The organic
layer was dried over MgSO4, ﬁltered and concentrated under re-
duced pressure. The resulting residue was puriﬁed by silica gel col-
umn chromatography using CH2Cl2 to obtain 14c as a yellow oil
(15 g, 75%): Rf 0.61 (CH2Cl2/MeOH, 98:2, v/v); IR cm1: 1700
(OC@O), 1669 (C@O, C@C); 1H NMR: d 7.25 (m, 5H), 6.29 (dd, 1H,
J = 21.58 Hz, J = 5.98 Hz), 5.42 (dd, 1H, J = 18.78 Hz, J = 6.01 Hz),
5.12 (s, 2H), 4.59 (s, 2H), 3.39 (t, 2H, J = 7.24 Hz), 1.33 (m, 2H),
1.18 (m, 22H), 0.81 (t, 3H, J = 6.32 Hz).
5.15. 1-Tetradecylpiperazin-2-one hydrochloride (15c)
To a solution of 14c (10.5 g, 24.6 mmol) in ethanol (100 mL)
were added 10% Pd–C (1 g) and concentrated hydrochloric acid
(5 mL). The suspension was shaken vigorously under H2 (50 PSI)
and heated to 40 C for 6 h. After cooling to room temperature
and ﬁltration through a glass frit funnel covered with a layer of Cel-
ite 545, the solvent was evaporated in vacuo and the resulting res-
idue was puriﬁed by crystallization in ether to afford 15c as a
yellow powder (7 g, 86%): mp 161,6 C (decomposed); Rf 0.24
(CH2Cl2/MeOH, 90:10, v/v); IR cm1: 3451 (NH2), 1655 (C@O); 1H
NMR: d 10.30–9.45 (ls, 1H), 8.90–7.70 (ls, 1H), 4.18 (m, 2H), 3.93
(m, 2H), 3.63 (m, 2H), 3.30 (m, 2H), 1.46 (m, 2H), 1.19 (m, 22H),
0.81 (t, 3H, J = 6.35 Hz).
5.16. 1-Tetradecylpiperazin-3-one (16c)
To a mixture of piperazin-2-one (1.9 g, 19 mmol) and potassium
carbonate (5.25 g, 38 mmol) in DMF (20 mL) was added dropwise a
solution of 1-bromotetradecane (5.28 g, 19 mmol) in DMF (20 mL).
After stirring for 24 h at room temperature, water (50 mL) was
added and the mixture was extracted with ether. The organic layer
was washed with brine, dried over MgSO4, then ﬁltered and con-
centrated in vacuo. The crude residue was puriﬁed by silica gel col-
umn chromatography using CH2Cl2/MeOH, 98:2, v/v, to give 16c as
a white powder (4.7 g, 83%): mp 87 C; Rf 0.48 (CH2Cl2/MeOH,
90:10, v/v); IR cm1: 3193 (NH), 1667(C@O); 1H NMR: d 6.32 (ls,
1H), 3.32 (m, 2H), 3.06 (s, 2H), 2.57 (t, 2H, J = 5.43 Hz), 2.34 (t,
2H, J = 7.35 Hz), 1.42 (m, 2H), 1.19 (m, 22H), 0.81 (t, 3H,
J = 6.46 Hz).
5.17. 1-Tetradecanoylpiperazin-3-one (17d)
A solution of piperazin-2-one (1 g, 10 mmol) and triethylamine
(1.7 mL, 12 mmol) in dichloromethane (80 mL) was stirred for
10 min at room temperature then cooled to 0 C and tetradecanoyl
chloride (3 mL, 11 mmol) was added. The reaction mixture was
stirred for 12 h at room temperature, then washed with a saturated
solution of NaHCO3 and water. The organic layer was dried over
MgSO4, ﬁltered and concentrated under reduced pressure. The
resulting residue was puriﬁed by crystallization in acetone to af-
ford 17d as a white powder (2.8 g, 90%): mp 77 C; Rf 0.26
3598 N. Meddad-Belhabich et al. / Bioorg. Med. Chem. 18 (2010) 3588–3600(CH2Cl2/MeOH, 93:7, v/v); IR cm1: 3204 (NH), 1670 (C@O), 1655
(C@O); 1H NMR: d 7.03–6.71 (ls, 1H), 4.18–4.07 (s, 2H), 3.75–3.61
(t, 2H, J = 5.20 Hz), 3.33 (t, 2H, J = 2.59 Hz), 2.25 (t, 2H,
J = 7.40 Hz), 1.57 (t, 2H, J = 7.40 Hz), 1.19 (m, 20H), 0.81 (t, 3H,
J = 6.39 Hz).
5.18. 1-Tetradecylpiperazine-2,5-dione (18c)
A solution of N-chloroacetylglycine ethyl ester (1 g, 5.57 mmol)
and 1-tetradecylamine (4.74 g, 22.3 mmol) in DMSO (58 mL) was
heated at 60 C for 48 h. After cooling to room temperature, water
(130 mL) was added and the mixture was extracted three times
with ether. The organic layer was dried over MgSO4, ﬁltered and
evaporated under reduced pressure. The crude residue was puri-
ﬁed by silica gel column chromatography using CH2Cl2/MeOH,
98:2, v/v, to obtain 18c as a white powder (1.4 g, 81%): mp
147 C; Rf 0.46 (CH2Cl2/MeOH, 90:10, v/v); IR cm1: 3260 (NH),
1677 (C@O), 1650 (NC@O); 1H NMR: d 6.93 (ls, 1H), 3.94 (s, 2H),
3.88 (s, 2H), 3.32 (t, 2H, J = 7.44 Hz), 1.49 (m, 2H), 1.19 (m, 22H),
0.81 (t, 3H, J = 6.44 Hz).
5.19. N-(2,2-Diethoxyethyl)-N0-tetradecyloxamide (19c)
A solution of N-(2,2-diethoxyethyl)oxamate ethyl ester (16.33 g,
70 mmol) and 1-tetradecylamine (14.9 g, 70 mmol) in ethanol
(250 mL) was stirred under argon atmosphere and heated to reﬂux
for 6 h. After cooling to room temperature, the mixture was ﬁltered
and the resulting solid was puriﬁed by crystallization in ethanol to
afford 19c as a yellow powder (21.5 g, 77%): mp 87.5–89 C; Rf 0.55
(CH2Cl2/MeOH, 97:3, v/v); IR cm1: 3302 (NH), 1688, 1650 (C@O),
1133, 1073 (C–O); 1H NMR: d 7.65 (t, 1H, J = 6.20 Hz), 7.55 (t, 1H,
J = 4.80 Hz), 4.47 (t, 1H, J = 5.40 Hz), 3.73–3.55 (m, 2H), 3.52–3.35
(m, 4H), 3.24 (q, 2H, J = 6.75 Hz), 1.48 (t, 2H, J = 6.81 Hz), 1.15 (m,
28H), 0.81 (t, 3H, J = 6.40 Hz).
5.20. 1,4-Dihydro-1-tetradecylpyrazine-2,3-dione (20c)
Compound 19c (21 g, 52.5 mmol) was dissolved in a mixture of
acetic acid (250 mL) and hydrochloric acid 12 N (0.55 mL). The
solution was heated to reﬂux for 30 min, and after cooling to room
temperature, evaporated in vacuo. The resulting residue was puri-
ﬁed by crystallization in CH2Cl2/MeOH to obtain 20c as a white
powder (15 g, 93%): mp 122 C (decomposed); Rf 0.25 (CH2Cl2/
MeOH, 97:3, v/v); IR cm1: 3225 (NH), 1665, 1640 (C@O), 1593
(C@C); 1H NMR: d 6.5 (d, 1H, J = 5.72 Hz), 6.15 (d, 1H, J = 5.8 Hz),
3.73 (t, 2H, J = 7.29 Hz), 1.64 (m, 2H), 1.18 (m, 22H), 0.80 (t, 3H,
J = 6.88 Hz).
5.21. 1-Tetradecylpiperazine-2,3-dione (21c)
To a suspension of 20c (6 g, 19.5 mmol) in ethyl acetate
(300 mL) was added 10% Pd–C (1 g). The mixture was shaken vig-
orously under H2 (50 PSI) and heated to 40–60 C for 48 h. After
cooling to room temperature and ﬁltration through a glass frit fun-
nel covered with a layer of Celite 545, the solvent was evaporated
in vacuo and the resulting yellow solid 21c was used without fur-
ther puriﬁcation: mp 101 C (decomposed); Rf 0.25 (CH2Cl2/MeOH,
93:7, v/v); IR cm1: 3239 (NH), 1698, 1671 (C@O); 1H NMR: d 8.17
(ls, 1H), 3.42 (m, 6H), 1.51 (m, 2H), 1.18–1.04 (m, 22H), 0.81 (t, 3H,
J = 6.52 Hz).
5.22. 1-(4-Chloromethylbenzoyl)-4-octadecanoylpiperazine
(22b)
A mixture of 1-octa decanoylpiperazine 2b (3.28 g, 9.3 mmol)
and Et3N (1.41 mL, 14 mmol) in CH2Cl2 (50 mL) was stirred at0 C for 10 min. A solution of 4-(chloromethyl)benzoyl chloride
(2.11 g, 11.16 mmol) in CH2Cl2 (25 mL) was added dropwise and
the mixture was stirred at room temperature for 2 h. The solution
was washed with a saturated Na2CO3 solution and twice with
water. After drying (MgSO4), ﬁltration and evaporation, the residue
was chromatographed on a silica gel column using CH2Cl2 as eluent
to yield 3.47 g (79%) of 22b as white crystals: mp 53 C; Rf 0.26
(CH2Cl2/MeOH, 95:5, v/v); IR cm1: 1662 (C@Oal), 1630 (C@Oar),
1600 (C@Car); 1H NMR: d 7.35 (q, 4H, J = 8.1 Hz), 4.57 (s, 2H),
3.8–3.3 (m, 8H), 2.31 (t, 2H, J = 7.3 Hz), 1.7–1.45 (m, 2H), 1.22 (ls,
28H), 0.85 (t, 3H, J = 6.1 Hz).
5.23. 1-(4-Cyanomethylbenzoyl)-4-octadecanoylpiperazine
(28b)
To a solution of 22b (3 g, 6 mmol) in dimethylsulfoxide (30 mL)
was added NaCN (1.16 g, 24 mmol) and the mixture was warmed
(80 C) for 2 h. After adding CH2Cl2 (30 mL), the solution was
washed twice with water, dried (MgSO4), ﬁltered and concentrated
in vacuo. The residue was chromatographed on a silica gel column
using MeOH/CH2Cl2 (99:1, v/v) as eluent to yield 1.9 g (64%) of the
nitrile 28b: mp 104 C; Rf 0.36 (CH2Cl2/MeOH, 90:10, v/v); IR cm1:
2251 (CN), 1675 (C@Oal), 1625 (C@Oar), 1600 (C@Car); 1H NMR: d
7.36 (q, 4H, J = 9.4 Hz), 3.80 (s, 2H), 3.49–3.58 (m, 8H), 2.3 (t, 2H,
J = 7.1 Hz), 1.56–1.62 (m, 2H), 1.21 (ls, 28H), 0.83 (t, 3H, J = 6.4 Hz).
5.24. 1-(4-Cyanomethylbenzyl)-4-(4-octadecyloxyphenyl)
piperazine (32a)
A mixture of 10a (3.28 g, 7 mmol), 4-bromomethylphenylaceto-
nitrile23 (1.52 g, 7 mmol), K2CO3 (2.5 g, 18.2 mmol) and KI (0.5 g) in
acetonitrile (200 mL) was heated to reﬂux for 6 h. The suspension
was ﬁltered and K2CO3 washed several times with CH2Cl2. The sol-
vents were evaporated under vacuo and the residue taken up in
CH2Cl2 (150 mL) was washed with water until neutral pH. After
drying (MgSO4), ﬁltration and evaporation, a crystallization in ace-
tone gave 2.60 g (66%) of 32a as white crystals: mp 100 C; Rf 0.6
(CH2Cl2/MeOH, 98:5, v/v); IR cm1: 2251 (CN), 1257 (C–O), 1600
(C@Car); 1H NMR: d 7.33 (q, 4H, J = 8.6 Hz), 6.86 (q, 4H,
J = 9.1 Hz), 3.89 (t, 2H, J = 6.52 Hz), 3.73 (s, 2H), 3.56 (s, 2H), 3.09
(t, 4H, J = 5 Hz) 2.60 (t, 4H, J = 5.1 Hz), 1.74 (q, 2H, J = 7 Hz), 1.25
(ls, 30H), 0.88 (t, 3H, J = 6.2 Hz).
5.25. 4-(2,2,2-Trichloroethoxycarbonylamino) phenylacetonitrile
(35)
A solution of 4-aminophenylacetonitrile (10 g, 75 mmol) in Et3N
(16 mL, 0.11 mol) and CH2Cl2 (100 mL) was cooled in an ice bath. A
solution of 2,2,2-trichloroethyl chloroformate (19.23 g, 90 mmol)
in CH2Cl2 (30 mL) was added dropwise and the mixture was stirred
at 0 C for 1 h. The solution was washed with a saturated Na2CO3
solution and twice with water. After drying (MgSO4), ﬁltration
and evaporation, the residue was crystallized in acetone/pentane
(10:90, v/v) to give 13.56 g (86%) of 35 as white crystals: mp
140 C; Rf 0.46 (CH2Cl2/MeOH, 99:1, v/v); IR cm1: 3306 (NH),
2256 (CN), 1642 (C@O), 1607 (C@Car); 1H NMR (DMSO-d6): d
10.20 (s, 1H), 7.4 (q, 4H, J = 8.4 Hz), 4.93 (s, 2H), 3.95 (s, 2H).
5.26. 4-(4-Cyanomethylbenzyl)-1-tetradecylpiperazin-2-one
(36c)
To a mixture of 1-tetradecylpiperazin-2-one hydrochloride 15c
(2.95 g, 8.8 mmol), K2CO3 (2.6 g, 17.6 mmol) and KI (0.5 g) in aceto-
nitrile (100 mL) was added 4-bromomethylphenylacetonitrile23
(2.2 g, 10 mmol). The reaction mixture was heated to reﬂux for
4 h, then ﬁltered and the solvent was removed in vacuo. The
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CO3 solution. The organic layer was dried over MgSO4, ﬁltered and
concentrated under reduced pressure. The crude residue was puri-
ﬁed by silica gel column chromatography using CH2Cl2/MeOH
(99:1, v/v) as eluent to give 36c as a yellow oil (3.6 g, 95%); Rf
0.48 (CH2Cl2/MeOH, 95:5, v/v); IR cm1: 2249 (CN), 1647 (CO),
1505 (C@C); 1H NMR: d 7.19 (m, 4H), 3.67 (s, 2H), 3.47 (s, 2H),
3.26 (m, 4H), 3.07 (s, 2H), 2.58 (t, 2H, J = 5.39 Hz), 1.47 (m, 2H),
1.18 (m, 22H), 0.81 (t, 3H, J = 6.40 Hz).
5.27. 4-(4-Chloromethylbenzoyl)-1-tetradecylpiperazin-2-one
(37c)
A solution of 1-tetradecylpiperazin-2-one hydrochloride 15c,
hydrochloride (6 g, 18 mmol) and triethylamine (7.6 mL, 54 mmol)
in benzene (140 mL) was cooled to 0 C and a solution of 4-chloro-
methylbenzoyl chloride (4.1 g, 21.6 mmol) in benzene (20 mL) was
added dropwise. The reaction mixture was allowed to warm to
room temperature and stirred for 2 h. The solvent was removed
in vacuo. The remaining residue was taken up in CH2Cl2 and
washed with a saturated Na2CO3 solution then with water. The or-
ganic layer was dried over MgSO4, ﬁltered and concentrated under
reduced pressure. The crude residue was puriﬁed by silica gel col-
umn chromatography using CH2Cl2/MeOH (99:1, v/v) to afford 37c
as a yellow powder (4.6 g, 57%): mp 60.5 C; Rf 0.28 (CH2Cl2/MeOH,
97:3, v/v); IR cm1: 1645 (CO), 1575 (C@C); 1H NMR: d 7.42–7.33
(m, 4H), 4.53 (s, 2H), 4.15 (ls, 2H), 3.81 (m, 2H), 3.33 (m, 4H),
1.49 (m, 2H), 1.18 (m, 22H), 0.81 (t, 3H, J = 6.39 Hz).
5.28. 1-(4-Cyanomethylbenzoyl)-1-tetradecylpiperazin-2-one
(38c)
The intermediate 37c (4.3 g, 9.6 mmol) was dissolved in DMSO
(67 mL) and the solution was cooled to 0 C. Sodium cyanide
(1.87 g, 38.3 mmol) was added in small portions and the reaction
mixture was heated to 50–55 C for 2 h. After cooling to room tem-
perature, water was added and the solution was extracted with
CH2Cl2. The organic layer was dried over MgSO4, ﬁltered and con-
centrated under reduced pressure. The resulting residue was puri-
ﬁed by silica gel column chromatography using CH2Cl2/MeOH
(99:1, v/v) as eluent to yield 38c as a brown oil (3.7 g, 88%): Rf
0.22 (CH2Cl2/MeOH, 97:3, v/v); IR cm1: 2251 (CN), 1649 (CO),
1575 (C@C); 1H NMR: d 7.43–7.32 (m, 4H), 4.12 (ls, 2H), 3.88 (m,
2H), 3.74 (s, 2H), 3.33 (m, 4H), 1.49 (m, 2H), 1.19 (m, 22H), 0.81
(t, 3H, J = 6.39 Hz).
5.29. 1-(4-Cyanobenzyl)-4-tetradecylpiperazin-2-one (39c)
Sodium hydride (60% dispersion in oil, 560 mg, 14 mmol) was
added to a stirred solution of 1-tetradecylpiperazin-3-one 16c
(3.47 g, 11.68 mmol) in freshly distilled THF (50 mL). The mixture
was stirred for 1 h at room temperature under argon atmosphere
and a solution of p-cyanobenzyle bromide (2.97 g, 15.2 mmol) in
THF (10 mL) was added dropwise at 0 C. After stirring for
30 min, the reaction mixture was allowed to warm to room tem-
perature and stirred for 18 h. MeOH (2 mL) was added and the sol-
vent was removed in vacuo. The resulting residue was taken up in
CH2Cl2 and washed with water. The organic layer was dried over
MgSO4, ﬁltered and evaporated under reduced pressure. The crude
residue was puriﬁed by silica gel column chromatography using
CH2Cl2/MeOH (99:1, v/v) to afford 39c as a white powder (4.3 g,
90%): mp 59.5 C; Rf 0.26 (CH2Cl2/MeOH, 97:3, v/v); IR cm1:
2230 (CN), 1638 (CO), 1596 (C@C); 1H NMR: d 7.55 (d, 2H,
J = 8.18 Hz), 7.30 (d, 2H, J = 8.19 Hz), 4.57 (s, 2H), 3.19 (t, 2H,
J = 5.52 Hz), 3.16 (s, 2H), 2.59 (t, 2H, J = 5.39 Hz), 2.32 (t, 2H,
J = 7.30 Hz), 1.41 (m, 2H), 1.19 (m, 22H), 0.81 (t, 3H, J = 6.33 Hz).5.30. 1-(4-N-Hydroxyamidinomethylbenzoyl)-4-octadecanoyl-
piperazine (43b)
To a solution of 28b (2 g, 4 mmol) in ethanol (50 mL) was added
NH2OH (50% w/w solution in water, 0.47 mL, 16 mmol). After
reﬂuxing at 80 C for 5 h, concentration to dryness afforded
2.15 g (97%) of amidoxime 43b as a yellow solid in sufﬁcient purity
for use in the next step without puriﬁcation: mp 128 C; Rf 0.44
(CH2Cl2/MeOH, 90:10, v/v); IR cm1: 3370 (OH), 3488 (NH), 1656
(C@Oal), 1634 (C@Oar), 1610 (C@N); 1H NMR: d 7.32 (s, 4H), 4.55
(s, 2H), 3.58–3.48 (m, 8H), 3.45 (s, 2H), 2.31 (t, 2H, J = 7.3 Hz),
1.45–1.65 (m, 2H), 1.23 (ls, 28H), 0.82 (t, 3H, J = 6.67 Hz).5.31. 1-[4-(4,5-Dihydro-1,2,4-(4H)-5-oxo-oxadiazol-3-ylmethyl)
benzoyl]-4-octadecanoyl piperazine (57b)
Phenyl chloroformate (0.75 g, 4 mmol) was added dropwise to
an ice-cooled mixture of amidoxime 43b (2.15 g, 4 mmol) and
Et3N (0.68 g, 4.8 mmol) in dry THF (30 mL). The resulting mixture
was stirred at 0 C for 1 h, the solvent was evaporated under re-
duced pressure and the residue, taken up in CH2Cl2, was washed
with a saturated Na2CO3 solution and twice with water. After dry-
ing (MgSO4), ﬁltration and evaporation, the residue was dissolved
in toluene and heated under reﬂux for 4 h. The reaction mixture
was concentrated in vacuo and the residue was chromatographed
on a silica gel column using CH2Cl2/MeOH (98:2, v/v) as eluent to
yield 1.5 g (68%) of 57b as white crystals: mp 94 C; Rf 0.51
(CH2Cl2/MeOH, 90:10, v/v); IR cm1: 3460 (N–H), 1780 (OCON),
1665 (C@Oal), 1636 (C@Oar), 1610 (C@N); 1H NMR: d 11.20 (s,
1H), 7.25 (s, 4H), 3.79 (s, 2H), 3.75–3.30 (m, 8H), 2.3 (t, 2H,
J = 4 Hz), 1.7–1.45 (m, 2H), 1.20 (ls, 28H), 0.82 (t, 3H, J = 5.9 Hz);
13C NMR : d 172.24, 170.23, 160.00, 157.69, 135, 134.03, 129.03,
127.48, 45.30, 41.33, 33.29, 31.73, 31.10, 29.51, 29.17, 25.11,
22.50, 13.95. Anal. (C32H50N4O4) C, H, N.5.32. 1-[4-(4,5-Dihydro-1,2,4-(4H)-5-oxo-oxadiazol-3-
ylmethyl)phenylaminocarbonyl]-4-octadecylpiperazine (71a)
A mixture of 64 (1.08 g, 3 mmol) and 1-octadecylpiperazine
6a23 (1 g, 3 mmol) in acetonitrile (20 mL) was heated to reﬂux
for 5 h. A white precipitate appeared and the hot suspension was
ﬁltered to yield 1 g of 71a (60%) as a beige powder: mp 160 C;
Rf 0.32 (CH2Cl2/MeOH, 90:10, v/v); IR cm1: 3356 (NH), 1788
(OCON), 1630 (C@O), 1597 (C@Car); 1H NMR: d 8.86 (s, 1H), 7.31
(q, 4H, J = 8.4 Hz), 3.79 (s, 2H), 3.33 (ls, 8H), 2.98 (t, 2H,
J = 7.9 Hz), 1.7–1.55 (m, 2H), 1.23 (ls, 30H), 0.85 (t, 3H,
J = 6.55 Hz); 13C NMR: d 159.76, 159.20, 154.55, 139.36, 128.82,
127.11, 119.85, 55.66, 50.72, 31.26, 30.00, 29.01, 28.79, 28.53,
26.11, 22.06, 13.93. Anal. (C32H53N5O3) C, H, N.5.33. 1-[4-(4,5-Dihydro-1,2,4-(4H)-5-oxo-oxadiazol-3-ylmethyl)
phenylaminocarbonyl]-4-octadecylaminocarbonylpiperazine
(72a)
Compound 72a was obtained in 56% yield following the same
procedure as for 71a but using 5a: mp 198 C; Rf 0.44 (CH2Cl2/
MeOH, 90:10, v/v); IR cm1: 3365 (NH), 1787 (OCON), 1632
(C@O), 1599 (C@Car); 1H NMR (DMSO-d6): d 8.55 (s, 1H), 7.42 (d,
2H, J = 8.2 Hz), 7.15 (d, 2H, J = 8.4 Hz), 6.5 (ls, 1H) 3.77 (s,
2H), 3.35 (ls, 8H), 2.99 (t, 2H, J = 5.72 Hz), 1.5–1.3 (m, 2H), 1.23
(m, 30H), 0.84 (t, 3H, J = 6.51 Hz); 13C NMR (DMSO-d6): d 160.10,
159.42, 157.36, 154.94, 139.64, 128.77, 126.89, 119.82, 43.54,
43.26, 31.29, 30.10, 29.80, 29.02, 28.70, 26.43, 22.09, 13.95. Anal.
(C33H54N6O4) C, H, N.
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